Arrest Made in Coldrif Cough Syrup Deaths Case
Authorities have arrested Dr Praveen Soni, the physician accused of prescribing the cough syrup Coldrif, which is linked to the deaths of children in Madhya Pradesh. Dr. Soni has been suspended from his post pending further inquiry.
What the Investigation Found
Laboratory tests found dangerously high levels of diethylene glycol (DEG) in Coldrif, far exceeding permissible limits. The batch in question—manufactured by Sresan Pharmaceuticals in Tamil Nadu—was declared “non-standard and defective.” State agencies in MP and Tamil Nadu have banned its sale and ordered all existing stocks to be sealed. A criminal probe into manslaughter, drug adulteration, and negligence has been launched against the manufacturer and prescribers.
Scope of the Tragedy
At least 14 children, most under the age of five, reportedly died after consuming the syrup and suffering acute kidney failure and other organ complications. Many had initially been treated for common cold symptoms. The deaths were recorded in Chhindwara district, with additional cases under review in nearby districts.
Regulatory and Judicial Reaction
The Central Drugs Standard Control Organisation (CDSCO) has directed stricter penalties and launched inspections across states. States such as Kerala, Telangana, and Rajasthan have already issued alerts and banned Coldrif from shops. Legal proceedings are expected to be fast-tracked given the public health urgency.
This incident has ignited fresh debate over drug safety and quality control in India’s pharmaceutical industry. With criminal cases underway, many are watching to see how accountability is enforced across the manufacturing and medical communities.
